As a pioneer of China’s epidemiology data provider, we fully understand how fragmented China’s epidemiology data can be. Draco strives to obtain and assess epidemiology data from the most reliable sources and publications of the highest quality. All of the data in Draco's epidemiology database is developed with international standard epidemiology methodologies (WHO Infobase, SEER and Globocan 2002). With yearly updated Epi information, we are committed to helping you understand the unique patient populations in China. The Chinese Epidemiology Reports are constantly being expanded to include new indications.

Draco’s epidemiology team has many years of experience in epidemiology research and has extensively researched and analyzed the major epidemiology publications in China. Draco is considered one of the best sources for Chinese epidemiology data by our satisfied clients, many of them are the major international pharmaceutical companies.

Draco’s China Epidemiology Database include:

• China Cancer Epidemiology Database
• China Non-cancer Disease Epidemiology Database

Top reasons why Draco’s Chinese epidemiology data are valuable:

• China's unique disease profiles
  • Large patient populations in several key diseases, such as liver diseases and certain cancers
  • Rising incidences in western-diseases such as diabetes, hypertension, depression, etc.

• Rapidly changing population profiles
  • Urbanization and aging have a direct effect on the epidemiologic trend
• Limited epidemiology researches
  • Many studies focused only on big cities
  • More prevalence studies, fewer incidence studies
• The Access-to-Care challenges posted by the economic development gap between urban and rural regions
  • Limited insurance coverage in rural China
  • Rapid expanding coverage with the goal of national coverage
  • Rapid growing of GDP and personal income levels

Key data presented in the China Prescription Drug (CPD©) Sales Database:

• Annual Sales (RMB and USD) of each therapeutic area (since 2005)
• Annual Sales (RMB and USD) of top 20 manufacturers in each therapeutic area (since 2005)
• Annual Sales (RMB and USD) and market shares of top drugs in each therapeutic area (since 2005)
• Annual Sales (RMB and USD) of top drugs by competing manuracturers (since 2005)
• Names, packages, prices and manufacturers of brand and generic drugs in each therapeutic area in China
• Drugs that are covered by the national healthcare insurance and worker’s injury insurance

Top reasons why Draco’s Chinese drug sales data are valuable:

• The most authoritative data of drug prescription/purchasing information on 19 key therapeutic areas, such as cancer, diabetes, hypertension, and other diseases of high interest in China.

• • All data is from the hospital data tracking system by the top medical information institute
• Annual syndicated reports on sales and market shares of top drugs and top pharmaceutical companies (international and domestic) in China.
  • Great cost/benefit value of these syndicated reports compared to customized reports on drug sales data in China.
• Sampled hospitals are from major Chinese cities throughout different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou.
• In total, these reports cover more than 150 of the top pharmaceutical companies (both international and Chinese domestic pharmaceutical companies).
• Significant percentages of in-patients and out-patients coverage. The coverage of in-patients and out-patients in sampled hospitals ranges from 16.72% to 66.07% for hospital beds and from 27.76% to 69.71% for out-patients.

Based on primary research with practicing oncologists in China and using data from published sources and our own expert coverage of major Chinese meetings and conferences, Treatment Architecture China assesses the current clinical management of cancer patients by site and stage for all treatment modalities—including surgical, radiologic, chemotherapeutic, and untreated populations.

CancerMPact® Treatment Architecture China is a clinical rich multi-client report that focuses on how cancers are treated in China. The 2009 reports and 2010 reports focus on the largest tumor types in China. The reports cover an in-depth analysis of treatment and drug utilization and provide an assessment of current clinical management of cancer by stage for all treatment modalities, including chemotherapy. The tumor-type reports are freestanding and include:

• Colorectal cancer
• Ovarian cancer
• Gastric cancer
• Hepatocellular carcinoma
• Non-small cell lung cancer
• Breast cancer
• Head and Neck cancer
• Pancreatic cancer
• Prostate cancer
• non-Hodgkin lymphoma
• Acute myeloid leukemia

Top Reasons why Draco’s China Cancer Treatment Architecture Reports are valuable:

• Clinical data rich, multi-client reports that focus on the largest tumor types in China
• In-depth analyses of treatment and drug utilization
• Assessment of current clinical management of cancer
  • By stage for all treatment modalities
  • By line of therapy, including chemotherapy regimens and biologics 
• Understanding of Chinese-specific standards of care is imperative for supporting strategic commercialization decisions in the dynamic and emerging oncology care market in China.